Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian equity markets trade volatile
Fri, 12 Sep 11:30 am

After opening firm, the benchmark Indian Indices have been witnessing volatility in the last two hours of trade. Amongst sectoral indices consumer durables and FMCG are witnessing buying interest. However, Metal and Power stocks are facing maximum selling pressure.

The BSE-Sensex is trading up 16 points. The NSE-Nifty is trading up 1 point. Both mid cap and small cap indices are in demand. The BSE Mid Cap index is trading up 0.14% and the BSE Small Cap index is trading up 0.41%. The rupee is trading at 60.94 to the US dollar.

Tata Group stocks are trading mixed with Titan Company and Tata Investment Corporation leading the gains. However, The Indian Hotels and Tata Communication are trading in the red. As per a leading financial daily, the Tata Group has set up a centralised platform that will facilitate collaboration and help tap synergies across its 100-plus group companies. Tata Sons, the apex investment holding company of the Tata Group, has put in place "clusters" and "enablers" to leverage on the resources, strength and expertise of group companies to enhance the overall performance of the group. While "clusters" focus on businesses with strong future growth prospects like retail, finance, infrastructure and defence & aerospace, "enablers" focus on specific domains like diversity, customer insight, internationalization and rural markets. This initiative will help the companies in boosting their growth prospects as well as on the cost saving front.

Indian pharma stocks are trading mixed with Ranbaxy Laboratories and Sun Pharma being among the leading losers, while Wockhardt Ltd and Cipla being among the leading losers. Cipla Ltd has announced that the company has entered into a commercial collaboration with S&D Pharma in Czech Republic and Slovakia. The collaboration will help Cipla to focus on core therapy areas, while S&D Pharma will be key partner for generics. Through this collaboration, Cipla will be launching its respiratory portfolio in both these markets, while S&D will help in distribution of these drugs. This will give Cipla an opportunity to develop its own brand in these markets. Cipla is also planning to launch combination inhalers in these markets once the necessary approvals and reimbursements are in place. Cipla is trading up by 1.88%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets trade volatile". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.